Keryx Biopharmaceuticals (NASDAQ:KERX) Release 1Q2017 Financial Results As It Looks To Expand Auryxia


Keryx Biopharmaceuticals (NASDAQ:KERX) has released its financial results for the 1Q2017, recording $11.8 million, in revenues. The company noted that $10.5 million of this amount came from the sale of Auryxia. Added to this, KERX claimed that it expects to record $56-$60 million in Auryxia sales, during the current year. It was also noted that Keryx would submit a New Drug Application, by the start of November 2017, to expand indications for ferric citrate.

Greg Madison, the CEO of the company, stated that they experienced significant prescription growth, during the 1Q2017, across the dialysis patient population. He also claimed that with a stronger brand awareness, broader patient access, they would be able to bring this medication to a larger patient population, suffering from hyperphosphatemia, on dialysis. Talking about the potential NDA, Mr. Madison revealed that it would be aimed at another chronic kidney disease, Iron Deficiency Anemia. The label is currently under review, but once approved, it would become the exclusive drug for the condition.

Keryx further revealed that it has been actively promoting the phase-3 results, for the use of ferric citrate, in patients with stage 3-5 NDD-CKD. So far, the company has highlighted these results in four poster presentations, at various conferences across the country. As far as KERX’s financials are concerned, it recorded a decline in R&D expenses, of $0.8 million on a year-over-year basis. The company claimed that the reduction was primarily attributed to the reduction of development work, at their contract manufacturer.

However, KERX recorded a surge of $2.3 million, in terms of its selling and general administrative expenses, on a year-over-year basis. The company noted that this was due to the continued commercialization of Auryxia and its potential expansion, later this year. Unfortunately, despite the rise in revenues, the company recorded a net loss of $23 million for its 1Q2017.

Keryx Biopharmaceuticals (NASDAQ:KERX) completed the May 4 trading session, with a gain of 6.56%, in terms of its share value, to close at $6.17 per share.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.